Corbus Pharmaceuticals Holdings (LTS:0SZI) Cyclically Adjusted Book per Share: $17.23 (As of Mar. 2026)


LTS:0SZI Corbus Pharmaceuticals Holdings Inc LTS:0SZI
47 GF Score
Price $9.61
GF Value $1.01
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Cyclically Adjusted Book per Share?

Corbus Pharmaceuticals Holdings LTS:0SZI +0.84% 47 Cyclically Adjusted Book per Share is $17.23 as of Mar. 2026. GuruFocus rates LTS:0SZI with a GF Score™ of 47/100 and a GF Value™ of $1.01 (Significantly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Corbus Pharmaceuticals Holdings's adjusted book value per share for the three months ended in Mar. 2026 was $7.122. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $17.23 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Corbus Pharmaceuticals Holdings's average Cyclically Adjusted Book Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-12), Corbus Pharmaceuticals Holdings's current stock price is $9.61. Corbus Pharmaceuticals Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $17.23. Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio of today is 0.56.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Corbus Pharmaceuticals Holdings was 0.57. The lowest was 0.00. And the median was 0.00.


Corbus Pharmaceuticals Holdings  (LTS:0SZI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.61/17.23
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Corbus Pharmaceuticals Holdings was 0.57. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Corbus Pharmaceuticals Holdings Cyclically Adjusted Book per Share Related Terms


Corbus Pharmaceuticals Holdings Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Cyclically Adjusted Book per Share Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 16.50 16.06 16.70

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.23 16.91 16.18 16.70 17.23

LTS:0SZI vs PRQR, NRXP, CRBU: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Cyclically Adjusted PB Ratio falls into.


LTS:0SZI
47GF Score
Corbus Pharmaceuticals Holdings Inc LTS:0SZI
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corbus Pharmaceuticals Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=7.122/330.2130*330.2130
=7.122

Current CPI (Mar. 2026) = 330.2130.

Corbus Pharmaceuticals Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201606 12.108 241.018 16.589
201609 9.082 241.428 12.422
201612 5.990 241.432 8.193
201703 26.084 243.801 35.329
201706 22.453 244.955 30.268
201709 19.104 246.819 25.559
201712 31.184 246.524 41.770
201803 34.404 249.554 45.524
201806 29.111 251.989 38.148
201809 22.469 252.439 29.391
201812 14.426 251.233 18.961
201903 19.684 254.202 25.570
201906 21.983 256.143 28.340
201909 13.748 256.759 17.681
201912 2.856 256.974 3.670
202003 9.392 258.115 12.015
202006 18.004 257.797 23.061
202009 10.666 260.280 13.532
202012 13.741 260.474 17.420
202103 21.957 264.877 27.373
202106 18.460 271.696 22.436
202109 18.598 274.310 22.388
202112 16.557 278.802 19.610
202203 14.648 287.504 16.824
202206 11.846 296.311 13.201
202209 10.045 296.808 11.176
202212 7.909 296.797 8.799
202303 3.905 301.836 4.272
202306 2.153 305.109 2.330
202309 0.070 307.789 0.075
202312 -1.561 306.746 -1.680
202403 9.229 312.332 9.757
202406 10.918 314.175 11.475
202409 12.357 315.301 12.941
202412 11.695 315.605 12.236
202503 10.390 319.799 10.728
202506 9.058 322.561 9.273
202509 7.351 324.800 7.474
202512 8.375 324.054 8.534
202603 7.122 330.213 7.122

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $17.23 mean?
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a Cyclically Adjusted Book per Share of $17.23 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Cyclically Adjusted Book per Share too high?
Corbus Pharmaceuticals Holdings' current Cyclically Adjusted Book per Share is $17.23. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Cyclically Adjusted Book per Share compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' Cyclically Adjusted Book per Share of $17.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Cyclically Adjusted Book per Share is $17.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (LTS:0SZI) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.01, compared to a current price of $9.61 — trading 851.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $17.23. Corbus Pharmaceuticals Holdings' overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current Cyclically Adjusted Book per Share is $17.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corbus Pharmaceuticals Holdings (LTS:0SZI) Overvalued in 2026?

Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued. The current stock price of $9.61 is trading 851.5% above its estimated GF Value™ of $1.01. GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.

Key valuation signals for LTS:0SZI:

  • Cyclically Adjusted Book per Share: $17.23
  • GF Value™: $1.01 vs. price of $9.61 (851.5% above fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the LTS:0SZI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
47GF Score

Get the complete analysis for LTS:0SZI

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.61
Price
$1.01
GF Value